<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2019.7134</article-id>
<article-id pub-id-type="publisher-id">or-42-01-0377</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The combination of temsirolimus and chloroquine increases radiosensitivity in colorectal cancer cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Shiratori</surname><given-names>Hiroshi</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/>
<xref rid="c1-or-42-01-0377" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Kawai</surname><given-names>Kazushige</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Hata</surname><given-names>Keisuke</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Toshiaki</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Nishikawa</surname><given-names>Takeshi</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Otani</surname><given-names>Kensuke</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Kazuhito</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Kaneko</surname><given-names>Manabu</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Murono</surname><given-names>Koji</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Emoto</surname><given-names>Shigenobu</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Sonoda</surname><given-names>Hirofumi</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Nozawa</surname><given-names>Hiroaki</given-names></name>
<xref rid="af1-or-42-01-0377" ref-type="aff"/></contrib>
</contrib-group>
<aff id="af1-or-42-01-0377">Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan</aff>
<author-notes>
<corresp id="c1-or-42-01-0377"><italic>Correspondence to</italic>: Dr Hiroshi Shiratori, Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan, E-mail: <email>tori.shior@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>07</month><year>2019</year></pub-date>
<pub-date pub-type="epub"><day>23</day><month>04</month><year>2019</year></pub-date>
<volume>42</volume>
<issue>1</issue>
<fpage>377</fpage>
<lpage>385</lpage>
<history>
<date date-type="received"><day>19</day><month>12</month><year>2018</year></date>
<date date-type="accepted"><day>19</day><month>04</month><year>2019</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2019, Spandidos Publications</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<abstract>
<p>The PI3K/AKT/mTOR pathway and autophagy are known to play important roles in cancer radioresistance. The aim of the present study was to investigate whether the combination of temsirolimus (TEM), an mTOR inhibitor, and chloroquine (CQ), an autophagy inhibitor, can increase radiosensitivity in colorectal cancer (CRC) cells. The efficacies of TEM and/or CQ as radiosensitizers were examined using clonogenic assays in CRC cell lines SW480 and HT-29. The expression levels of the phosphorylated isoforms of S6 and 4E-BP1, downstream proteins of mTOR, as well as the expression levels of p62 and LC3, autophagy-related proteins, were assessed by western blot analysis. The formation of acidic organelles was detected in acridine orange-stained cells. Apoptosis and caspase activity were assessed using flow cytometry. The results revealed that ionizing radiation (IR) activated the downstream proteins of mTOR and induced autophagy. In the clonogenic assays, neither TEM nor CQ influenced the efficacy of IR, whereas their combination significantly increased the dose-dependent efficacy of IR. TEM inhibited phosphorylation of the downstream proteins of mTOR and induced autophagy. CQ inhibited autophagy in the late phase and did not influence the downstream proteins of mTOR. TEM and CQ inhibited both the phosphorylation of downstream proteins of mTOR and autophagy. Cell death analysis revealed that the combination of TEM and CQ strongly induced apoptosis in cells exposed to IR. In conclusion, the combination of TEM and CQ increased radiosensitivity in CRC cells through co-inhibition of mTOR and autophagy.</p>
</abstract>
<kwd-group>
<kwd>colorectal cancer</kwd>
<kwd>radiosensitivity</kwd>
<kwd>mTOR</kwd>
<kwd>autophagy</kwd>
<kwd>temsirolimus</kwd>
<kwd>chloroquine</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Preoperative chemoradiotherapy (CRT) is considered a standard therapy for local control in patients with locally advanced rectal cancer. Pathological complete response (pCR) in the patients treated with CRT implies the absence of residual cancer in the resected specimen. Since the recurrence rate after curative surgery in the patients with pCR has been reported to be lower than that in non-responders (<xref rid="b1-or-42-01-0377" ref-type="bibr">1</xref>), increasing the pCR rate is necessary to improve patient prognosis. However, 5-FU-based conventional CRT has been revealed to result in pCR for only 13&#x2013;17 &#x0025; of patients (<xref rid="b2-or-42-01-0377" ref-type="bibr">2</xref>), and these results are insufficient. Hence, chemotherapeutic regimens for increasing tumor radiosensitivity are being investigated worldwide.</p>
<p>Preclinical studies on solid cancer cells revealed that ionizing radiation (IR) activated the PI3K/AKT/mTOR signaling pathway, which was considered to be one of the radioresistance mechanisms (<xref rid="b3-or-42-01-0377" ref-type="bibr">3</xref>,<xref rid="b4-or-42-01-0377" ref-type="bibr">4</xref>). However, in a phase-II clinical trial for patients with locally advanced rectal cancer, CRT combined with rapamycin, an mTOR inhibitor, resulted in pCR in 3&#x0025; of patients and the radiosensitizing effect of mTOR inhibitor was not observed (<xref rid="b5-or-42-01-0377" ref-type="bibr">5</xref>).</p>
<p>An mTOR inhibitor is known to induce autophagy by dephosphorylating UNC-51-like kinase (ULK1). Autophagy is considered as a cause for chemo/radiotherapy resistance in cancer cells due to its function of self-protection and self-degradation (<xref rid="b6-or-42-01-0377" ref-type="bibr">6</xref>,<xref rid="b7-or-42-01-0377" ref-type="bibr">7</xref>). This cytoprotective function of autophagy was reported to play a role in resistance to the antitumor effect of mTOR inhibitor (<xref rid="b8-or-42-01-0377" ref-type="bibr">8</xref>). In addition, in a previous study, it was demonstrated that the combination of temsirolimus (TEM), an mTOR inhibitor, and chloroquine (CQ), an autophagy inhibitor, improved the antitumor effect in colorectal cancer (CRC) cells (<xref rid="b9-or-42-01-0377" ref-type="bibr">9</xref>). Based on this result, we hypothesized that the simultaneous inhibition of mTOR signaling and autophagy is essential to enhance radiosensitivity. Therefore, in the present study, we aimed to determine whether the co-inhibition of mTOR and autophagy using TEM and CQ enhanced radiosensitivity in CRC cells.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture and reagents</title>
<p>The human CRC cell lines, HT-29 and SW480, were purchased from the Japanese Cancer Research Resource Bank. Cells were cultured in RPMI-1640 medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 5&#x0025; fetal bovine serum (FBS) and 1&#x0025; antibiotic/antimycotic solution in a 5&#x0025; CO<sub>2</sub> incubator at 37&#x00B0;C. The mTOR inhibitor TEM and the autophagy inhibitor chloroquine diphosphate (CQ) were purchased from Sigma-Aldrich; Merck KGaA. Rabbit antibodies against phospho-S6 ribosomal protein (Ser235/236), S6 ribosomal protein (5G10), phospho-eukaryotic translation initiation factor 4E-binding protein 1 (phospho-4E-BP1; Thr37/46), and 4E-BP1 were purchased from Cell Signaling Technology (Tokyo, Japan); those against microtubule-associated protein light chain 3 beta (LC3B), protein 62 [p62; also known as sequestosome-1 (SQSTM1)], and &#x03B2;-actin were obtained from Medical and Biological Laboratories (MBL, Nagoya, Japan); and alkaline phosphatase-labeled goat anti-rabbit antibody was purchased from Abcam (Cambridge, UK).</p>
</sec>
<sec>
<title>Preparation of radiosensitizers and exposure to IR</title>
<p>The experimental doses of TEM and CQ were determined to be 80 nM and 20 &#x00B5;M, respectively based on a previous study (<xref rid="b9-or-42-01-0377" ref-type="bibr">9</xref>). The cells were pretreated with TEM (TEM group), CQ (CQ group), both (TEM&#x002B;CQ group), or no treatment (the control group) for 1 h before exposure to IR. Cells were irradiated at doses of ~6 Gy (1.0 Gy/sec) with an X-ray generator (Pantac HF350; Kyoto, Japan). Irradiated cells were used in subsequent experiments. The experimental radiation dose was determined according to several preceding studies (<xref rid="b10-or-42-01-0377" ref-type="bibr">10</xref>&#x2013;<xref rid="b12-or-42-01-0377" ref-type="bibr">12</xref>), including our previous study using colorectal cell lines (<xref rid="b13-or-42-01-0377" ref-type="bibr">13</xref>).</p>
</sec>
<sec>
<title>Clonogenic assay</title>
<p>The SW480 and HT-29 cells from each group were seeded at densities of 200-1,200 cells in a 6-well plate. Cells were pretreated with or without TEM and/or CQ for 1 h followed by exposure to IR at doses of 0, 2, 4 or 6 Gy. After incubation for 24 h, the medium was changed to a fresh one without drugs. The medium was then changed to a fresh one every 48 h for 14 days. Then, the cells were fixed with 70&#x0025; ethanol at room temperature for 30 min, and stained with 0.5&#x0025; crystal violet solution at room temperature for 30 min, and the colonies were counted. The surviving fraction (SF) in each group was calculated as follows: SF=no. of colonies with IR/no. of colonies without IR. For each experimental condition, colonies from three different wells were counted. All SF values were expressed as the mean &#x00B1; standard deviation (SD).</p>
</sec>
<sec>
<title>Cell proliferation assay</title>
<p>SW480 and HT-29 cells (5&#x00D7;10<sup>4</sup> cells/well) were seeded in 96-well flat-bottomed plates and incubated for 72 h with or without TEM and/or CQ after exposure to IR at a dose of 4 Gy. Then, MTS reagent (Promega Corp., Madison, WI, USA) was added to each well, cells were incubated for 3 h, and spectrophotometric assessment was performed with a 490-nm filter using Varioskan Flash, a microplate reader (Life Technologies; Thermo Fisher Scientific, Inc.). All experiments were performed in triplicate wells, and the data for cell proliferation were expressed as the mean &#x00B1; SD.</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>SW480 and HT-29 cells were incubated for 24 h with or without TEM and/or CQ after exposure to IR at a dose of 4 Gy. Whole cell protein extracts were obtained by lysing cells in Bolt LDS sample buffer (Life Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with protease and phosphatase inhibitors (Roche Diagnostics, Basel, Switzerland). Solubilized proteins were quantified using the Qubit protein assay kit (Life Technologies; Thermo Fisher Scientific, Inc.) and 40 &#x00B5;g of protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with 4&#x2013;12 &#x0025; Bis-Tris Gel (Life Technologies; Thermo Fisher Scientific, Inc.) and transferred to polyvinylidene difluoride (PVDF) membranes (pore size 0.2 &#x00B5;m) using the Bolt system (Life Technologies; Thermo Fisher Scientific, Inc.). After blocking with the iBind solution (Life Technologies; Thermo Fisher Scientific, Inc.) at room temperature for 5 min, western blotting was performed using the iBind Western System (Life Technologies; Thermo Fisher Scientific, Inc.), according to the manufacturer&#x0027;s instructions; the membranes were incubated with rabbit antibodies against phospho-S6 ribosomal protein (Ser235/236; dilution 1:1,000; cat. no. 4857), S6 ribosomal protein (5G10; dilution 1:1,000; cat. no. 2217), phospho-4E-BP1 (Thr37/46; dilution 1:1,000; cat. no. 2855), 4E-BP1 (dilution 1:1,000; cat. no. 9452) all from CST; LC3B (dilution 1:1,000; cat. no. PM036), p62, also known as sequestosome-1 (SQSTM1) (dilution 1:1,000; cat. no. PM045), or &#x03B2;-actin (dilution 1:1,000; cat. no. PM053) all from MBL at room temperature for 3 h, followed by alkaline phosphatase-labeled goat anti-rabbit antibody (dilution 1:2,000; cat. no. ab97048; Abcam) at room temperature for 2 h. The membranes were incubated in CDP-Star solution (Life Technologies; Thermo Fisher Scientific, Inc.) for 5 min, and chemiluminescence was detected using ChemiDoc XRS system (Bio-Rad Laboratories, Inc., Tokyo, Japan). The experiment was performed three times. The density of each band was measured using ImageJ software (version 1.4.3; National Institutes of Health, Bethesda, MD, USA) and expressed as the mean &#x00B1; SD. The phosphorylated isoform fraction of S6 and 4E-BP1 were normalized by the respective total protein levels.</p>
</sec>
<sec>
<title>Acidic vesicular organelle (autophagosome) detection</title>
<p>SW480 and HT-29 cells were prepared and treated as aforementioned. The cells were collected in FACS tubes and stained with 5 &#x00B5;g/ml acridine orange (Sigma-Aldrich; Merck, Tokyo, Japan) for 15 min at room temperature. Then, the samples were washed twice with Ca<sup>2&#x002B;</sup>/Mg<sup>2&#x002B;</sup>-free phosphate-buffered saline [PBS(&#x2212;)] and immediately analyzed using a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA), or examined under a fluorescence microscope (BZ-8100; Keyence Corp., Tokyo, Japan). The experiments were performed three times. All numerical data were expressed as the mean &#x00B1; SD.</p>
</sec>
<sec>
<title>Apoptosis and cell death analysis</title>
<p>SW480 and HT-29 cells were prepared and treated as aforementioned, and the harvested cells were stained with a combination of Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) (Annexin V-FITC apoptosis detection kit; BD Biosciences), according to the manufacturer&#x0027;s instructions. The samples were immediately analyzed by flow cytometer. This method allows the distinction between cells in early (Annexin V-FITC<sup>&#x002B;</sup>/PI<sup>&#x2212;</sup>) and late (Annexin V-FITC<sup>&#x002B;</sup>/PI<sup>&#x002B;</sup>) apoptosis; however, in the present study, these subpopulations were counted together and expressed as a fraction of the apoptotic cells. Next, for the quantification of caspase-3/7 activity, cells were labeled with CellEvent caspase-3/7 green detection reagent (Life Technologies; Thermo Fisher Scientific, Inc.) and analyzed by flow cytometry. Alternatively, for calculating the proportion of dead cells, the cells were stained with trypan blue (Sigma-Aldrich; Merck KGaA), and dead cells (stained with trypan blue) and alive cells (unstained cells) were counted immediately. All experiments were performed three times, and all data were expressed as the mean &#x00B1; SD.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Statistical significance of the differences was determined using the unpaired, two-tailed Student&#x0027;s t-test for single comparisons and one-way ANOVA followed by Tukey&#x0027;s post hoc test for multiple comparisons. In addition, the interactions of radiation levels and different drug therapies were analyzed by two-way ANOVA. All analyses were performed using the JMP Pro 13.0 software (SAS Institute, Inc., Cary, NC, USA). Differences with P&#x003C;0.05 were considered statistically significant.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>IR activates the mTOR signaling pathway and induces autophagy in CRC cells</title>
<p>To investigate whether IR activates the mTOR signaling pathway and induces autophagy in human CRC cell lines, the levels of mTOR pathway-related proteins and autophagy-related proteins in SW480 and HT-29 cells before and after IR exposure were determined by western blotting (<xref rid="f1-or-42-01-0377" ref-type="fig">Fig. 1A and B</xref>). The levels of the phosphorylated isoforms of mTOR pathway-related proteins, S6 ribosomal protein and 4E-BP1, normalized by the respective total proteins, were significantly increased after IR exposure in both cell lines, indicating that IR activated the mTOR signaling pathway in CRC cells. Similarly, conversion of LC3-I to LC3-II, which plays an important role in autophagosome formation, was observed, and the LC3-II/LC3-I ratios increased after IR exposure, whereas the levels of p62, which is consumed during autophagy, decreased after IR exposure, in both cell lines. These results indicate that IR induced autophagy in CRC cells. The time-dependent levels of p-S6 normalized by total S6 protein (p-S6/total S6 ratios) and LC3-II/LC3-I ratios in cells after the IR exposure are displayed in <xref rid="f1-or-42-01-0377" ref-type="fig">Fig. 1C and D</xref>. In both the cell lines, p-S6/total S6 ratios increased immediately after IR exposure and then decreased at 48 h after exposure, whereas LC3-II/LC3-I ratios increased slowly and remained high at 48 h after IR exposure. Similarly, the number of acidic autophagosomes stained with acridine orange significantly increased after IR exposure in a time-dependent manner, in both cell lines (<xref rid="f1-or-42-01-0377" ref-type="fig">Fig. 1E and F</xref>).</p>
</sec>
<sec>
<title>TEM and CQ combination therapy increases radiosensitivity in CRC cells</title>
<p>Next, whether mTOR inhibition and/or autophagy inhibition increases radiosensitivity in CRC cells was investigated, by studying the dose-dependent efficacies of IR in cells with or without TEM and/or CQ. In the clonogenic assay (<xref rid="f2-or-42-01-0377" ref-type="fig">Fig. 2A and B</xref>), a two-way ANOVA revealed the interaction of radiation levels and drug therapies in SW480 cells (P&#x003C;0.001) and HT-29 cells (P&#x003C;0.001). Although CQ or TEM monotherapy did not affect the suppressive effect of irradiation, the combination of TEM and CQ significantly enhanced the radiosensitivity at 2, 4 and 6 Gy in SW480 cells and at 4 and 6 Gy in HT-29 cells. In the MTS assay, TEM or CQ treatment in cells exposed to IR decreased cell proliferation, compared to that observed with IR exposure alone (<xref rid="f2-or-42-01-0377" ref-type="fig">Fig. 2C</xref>). Moreover, cell proliferation after the combination therapy of TEM and CQ was lower than that observed after the monotherapies with TEM or CQ.</p>
</sec>
<sec>
<title>TEM and CQ combination therapy inhibits the activation of mTOR pathway and autophagy in IR-exposed cells</title>
<p>Next, the levels of mTOR pathway-related proteins and autophagy-related proteins in each group were assessed (<xref rid="f3-or-42-01-0377" ref-type="fig">Fig. 3A and B</xref>). The levels of IR-induced phosphorylated isoforms of S6 and 4E-BP1 significantly decreased after TEM monotherapy but were not affected by CQ monotherapy. The IR-induced conversion of LC3-I to LC3-II significantly increased after CQ or TEM treatment and the LC3-II/LC3-I ratios were the highest after TEM and CQ combination therapy. Furthermore, p62 consumed by IR decreased after TEM monotherapy but increased after CQ monotherapy and was the highest after the combination therapy. Furthermore, acridine orange staining revealed that the number of IR-induced acidic autophagosomes increased after treatment with a combination of TEM and CQ, compared to that observed after monotherapy with TEM or CQ (<xref rid="f3-or-42-01-0377" ref-type="fig">Fig. 3B</xref>). These results were demonstrated in both SW480 and HT-29 cells.</p>
</sec>
<sec>
<title>TEM and CQ combination therapy induces apoptosis in IR-exposed cells</title>
<p>To analyze cell death in each group, apoptosis was analyzed via double staining with &#x0391;nnexin V-FITC and PI (<xref rid="f4-or-42-01-0377" ref-type="fig">Fig. 4A</xref>). The proportion of apoptotic cells, as Annexin V-positive cells, in each group are displayed in <xref rid="f4-or-42-01-0377" ref-type="fig">Fig. 4B</xref>. The apoptosis rate after IR exposure alone (5.5&#x0025;) was significantly higher than that of the control (3.1&#x0025;), which indicated that IR induced apoptosis in SW480 cells. TEM or CQ treatment with IR exposure in SW480 cells increased the apoptotic rate to 6.6 and 7.4&#x0025;, respectively, but these differences were not significant; however, treatment with a combination of TEM and CQ with IR exposure significantly increased the apoptotic rate up to 14.3&#x0025;, compared to that observed after IR exposure with or without TEM or CQ single agents. Similarly, the proportion of dead cells stained with trypan blue in SW480 cells treated with IR and a combination of TEM and CQ (5.2&#x0025;) were significantly higher than those in the control cells (1.1&#x0025;) and cells treated with IR alone (2.5&#x0025;), TEM alone (2.9&#x0025;), and CQ alone (3.3&#x0025;; <xref rid="f4-or-42-01-0377" ref-type="fig">Fig. 4D</xref>). The proportion of activated caspase-3/7 in SW480 cells treated with IR and a combination of TEM and CQ (15.5&#x0025;) were significantly higher than those in control cells (3.5&#x0025;) and cells treated with IR alone (7.0&#x0025;), TEM alone (9.3&#x0025;), and CQ alone (11.0&#x0025;; <xref rid="f4-or-42-01-0377" ref-type="fig">Fig. 4C</xref>). Furthermore, similar results were obtained from HT-29 cells.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The PI3K/AKT/mTOR pathway is an intracellular signaling pathway involving the phosphorylation of proteins downstream of tyrosine kinase receptors, resulting in phosphorylation of ribosomal protein S6 and 4E-BP1 (<xref rid="b14-or-42-01-0377" ref-type="bibr">14</xref>). In cancer cells, the activation of mTOR signaling promotes tumor growth and angiogenesis and inhibits apoptosis (<xref rid="b14-or-42-01-0377" ref-type="bibr">14</xref>,<xref rid="b15-or-42-01-0377" ref-type="bibr">15</xref>). Furthermore, the PI3K/AKT/mTOR pathway and autophagy are known to play important roles in cancer radioresistance. In the present study, the effect of TEM (mTOR inhibitor) and CQ (autophagy inhibitor) combination therapy was investigated on the radiosensitivity of CRC cells.</p>
<p>In the present study, S6 and 4E-BP1 were phosphorylated after IR exposure with a peak at 24&#x2013;36 h after IR exposure, indicating that mTOR signaling was activated by IR. The activation of mTOR signaling by IR has been reported in endometrial and breast cancer cells as well as human umbilical vein endothelial cells (<xref rid="b3-or-42-01-0377" ref-type="bibr">3</xref>,<xref rid="b16-or-42-01-0377" ref-type="bibr">16</xref>,<xref rid="b17-or-42-01-0377" ref-type="bibr">17</xref>) but not in CRC cells. Since mTOR inhibitor has been reported to inhibit the repair of IR-induced DNA damage in breast cancer cells, mTOR signaling activated by IR is considered to play an important role in radioresistance (<xref rid="b4-or-42-01-0377" ref-type="bibr">4</xref>).</p>
<p>Generally during the autophagic process, the autophagy substrate SQSTM1/p62 is consumed, LC3 is converted from its isotype I to II, and acidic organelles are accumulated in the cell (<xref rid="b18-or-42-01-0377" ref-type="bibr">18</xref>,<xref rid="b19-or-42-01-0377" ref-type="bibr">19</xref>). In particular, the LC3-II/LC3-I ratio is considered an important parameter to evaluate the degree of autophagy. In the present study, p62 levels decreased and the LC3-II/LC3-I ratios and accumulation of acidic organelles increased with a peak at 36 h after IR exposure, indicating that autophagy was induced by IR. These results are consistent with previous studies on IR-induced autophagy in many solid cancer cells, including CRC cells, indicating that IR-induced autophagy may play a cytoprotective role (<xref rid="b10-or-42-01-0377" ref-type="bibr">10</xref>&#x2013;<xref rid="b12-or-42-01-0377" ref-type="bibr">12</xref>).</p>
<p>Several studies have reported the irradiation-induced activation of the mTOR pathway (<xref rid="b3-or-42-01-0377" ref-type="bibr">3</xref>,<xref rid="b16-or-42-01-0377" ref-type="bibr">16</xref>,<xref rid="b17-or-42-01-0377" ref-type="bibr">17</xref>) and autophagy pathway (<xref rid="b10-or-42-01-0377" ref-type="bibr">10</xref>&#x2013;<xref rid="b12-or-42-01-0377" ref-type="bibr">12</xref>) in different cell lines, despite the suppressive effect of the activated mTOR pathway on autophagy. It has been reported that autophagy can be induced via several pathways after radiation, such as those involving accumulation of reactive oxygen (ROS), calcium ions and mitochondrial damage (<xref rid="b7-or-42-01-0377" ref-type="bibr">7</xref>). The present results indicated that irradiation induced autophagy activation independently of the mTOR pathway and that this activation overcame the suppressive effect of the mTOR pathway; however, further studies are warranted to confirm this. TEM treatment in combination with irradiation increased the LC3-II/LC3-I ratio and p62 consumption (<xref rid="f3-or-42-01-0377" ref-type="fig">Fig. 3</xref>), indicating the suppressive effect of the mTOR pathway on autophagy and enhancement of autophagy by mTOR inhibition.</p>
<p>Next, a clonogenic assay was performed using TEM and/or CQ, to determine whether the inhibition of mTOR signaling and/or autophagy increases radiosensitivity in CRC cells. In both SW480 and HT-29 cells, neither TEM nor CQ monotherapy influenced the effect of radiation, but the interaction of the combination of TEM and CQ and radiation levels was demonstrated by two-way ANOVA. Western blotting revealed that TEM alone inhibited IR-induced mTOR signaling but induced autophagy, as indicated by decreased p62 and increased LC3-II/LC3-I ratios. mTOR is known to be a strong factor for inhibiting autophagy; mTOR C1 phosphorylates ULK1 and suppresses its function, which in turn suppresses the formation of autophagosomes (<xref rid="b7-or-42-01-0377" ref-type="bibr">7</xref>). An mTOR inhibitor has been reported to induce autophagy by dephosphorylating ULK1 and promoting the formation of autophagosomes. In contrast, CQ alone was revealed to increase the level of p62, indicating autophagy inhibition since CQ inhibits autophagy in its late phase (<xref rid="b9-or-42-01-0377" ref-type="bibr">9</xref>,<xref rid="b20-or-42-01-0377" ref-type="bibr">20</xref>). As anticipated, CQ monotherapy did not affect the levels of pS6 and p4E-BP1, suggesting that CQ does not influence mTOR signaling. Cells treated with a combination of TEM and CQ revealed the highest levels of p62 and LC3-II/LC3-I ratios, confirming the inhibition of IR-activated mTOR signaling by TEM and the late phase inhibition of TEM-induced autophagy by CQ. Therefore, autophagy induction after TEM treatment and active mTOR signaling after CQ treatment indicate that TEM or CQ alone does not affect the radiosensitivity of cells and that both inhibition of mTOR and autophagy collectively enhance radiosensitivity. Although the radiosensitizing effect of the mTOR inhibitor alone was reported in pancreatic, breast, and prostate cancer cells via <italic>in vivo</italic> and <italic>in vitro</italic> studies (<xref rid="b3-or-42-01-0377" ref-type="bibr">3</xref>,<xref rid="b21-or-42-01-0377" ref-type="bibr">21</xref>,<xref rid="b22-or-42-01-0377" ref-type="bibr">22</xref>), the radiosensitizing effect of rapamycin was not observed in a clinical trial of rectal cancer (<xref rid="b5-or-42-01-0377" ref-type="bibr">5</xref>). Similarly, the radiosensitizing effect of autophagy inhibitor 3-MA was reported in breast cancer cells (<xref rid="b23-or-42-01-0377" ref-type="bibr">23</xref>), but CQ did not affect radiosensitivity in CRC cells (<xref rid="b24-or-42-01-0377" ref-type="bibr">24</xref>). According to these studies, the radiosensitizing effects of an mTOR inhibitor alone or CQ alone differed among the cell lines (<xref rid="b25-or-42-01-0377" ref-type="bibr">25</xref>). In contrast, the combination of an mTOR inhibitor and CQ was reported to improve the anti-proliferative effect in several cells, including CRC cells (<xref rid="b26-or-42-01-0377" ref-type="bibr">26</xref>,<xref rid="b27-or-42-01-0377" ref-type="bibr">27</xref>), however, the radiosensitizing effect of this combination has not yet been reported. Hence, it was considered that inhibition of mTOR signaling or autophagy alone was insufficient for enhancing radiosensitivity, but co-inhibition of both these processes is essential in CRC cells.</p>
<p>Cell death analysis revealed a significantly high apoptosis rate after TEM and CQ combination therapy but not after TEM or CQ monotherapy. Previous studies reported the preservation of phosphorylated AKT, an anti-apoptotic protein after treatment with an mTOR inhibitor, indicating that it does not induce apoptosis (<xref rid="b28-or-42-01-0377" ref-type="bibr">28</xref>). Autophagy maintains the quality of mitochondria, thus preventing the accumulation of intracellular ROS (<xref rid="b7-or-42-01-0377" ref-type="bibr">7</xref>). Although autophagic inhibition has been reported to induce apoptosis through aberrant ROS accumulation, in the present study no significant increase was revealed in the apoptosis rates after treatment with CQ alone. In contrast, the combination of an mTOR inhibitor and CQ was reported induce apoptosis in a synergistic manner, consistent with the results obtained in our study (<xref rid="b8-or-42-01-0377" ref-type="bibr">8</xref>,<xref rid="b9-or-42-01-0377" ref-type="bibr">9</xref>,<xref rid="b27-or-42-01-0377" ref-type="bibr">27</xref>). An mTOR inhibitor induces autophagosome formation and CQ leads to the permeabilization of the autophagosome membrane, resulting in the induction of apoptosis (<xref rid="b29-or-42-01-0377" ref-type="bibr">29</xref>&#x2013;<xref rid="b31-or-42-01-0377" ref-type="bibr">31</xref>). In the present study, the accumulation of autophagosomes was observed in IR-exposed cells, but the accumulation was enhanced in cells treated with IR and TEM. Thus, it was hypothesized that adding CQ in the presence of excessive autophagosome accumulation may contribute to increased apoptosis via autophagosome membrane permeabilization.</p>
<p>There are several limitations of the present study. First, this is an <italic>in vitro</italic> study, and the findings from an <italic>in vivo</italic> study may not be consistent with our findings. Furthermore, although the safety of the combination of TEM and CQ has been demonstrated in a phase-I clinical study for several solid cancers (<xref rid="b32-or-42-01-0377" ref-type="bibr">32</xref>), clinical studies investigating the effect of this combination on radiosensitivity have not yet been performed, and prospective clinical trials are warranted to confirm our results. Second, the radiosensitizing effect of the combination of TEM and CQ in this study may be attributed to their unique effects, and a combination of other mTOR and autophagy inhibitors may not yield results consistent with those obtained in the present study. Therefore, future investigations using various mTOR and autophagy inhibitors are required. This study would be greatly strengthened by future validating studies using clinical colorectal cancer tissues or colorectal cancer xenograft <italic>in vivo</italic> models, which were beyond the scope of the present study.</p>
<p>In conclusion, the radiosensitizing effect of the combination of TEM and CQ was demonstrated in CRC cells. This combination therapy may be considered as an effective chemotherapy combined with radiotherapy in patients undergoing neoadjuvant CRT for rectal cancer.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>The present study was supported by Grants-in-Aid for Scientific Research (grant nos. 16K07143, 16K07161, 17K10620, 17K10621, 17K10623 and 18K07194) from the Japan Society for the Promotion of Science. This research was also supported by the Project for Cancer Research and Therapeutic Evolution (P-CREATE; grant no. 18cm0106502h0003) from the Japan Agency for Medical Research and Development (AMED).</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>All datasets generated during this study are included in this published article.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>HSh, KK, KH and HN aided in the concept and design of the project. HSh, TT, TN, KO, KS, MK, KM, SE and HSo contributed to manuscript preparation and data collection. HSh and KK interpreted the results, analyzed the data, and revised the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-or-42-01-0377"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>ST</given-names></name><name><surname>Heneghan</surname><given-names>HM</given-names></name><name><surname>Winter</surname><given-names>DC</given-names></name></person-group><article-title>Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer</article-title><source>Br J Surg</source><volume>99</volume><fpage>918</fpage><lpage>928</lpage><year>2012</year><pub-id pub-id-type="doi">10.1002/bjs.8702</pub-id><pub-id pub-id-type="pmid">22362002</pub-id></element-citation></ref>
<ref id="b2-or-42-01-0377"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x00F6;del</surname><given-names>C</given-names></name><name><surname>Liersch</surname><given-names>T</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Fietkau</surname><given-names>R</given-names></name><name><surname>Hohenberger</surname><given-names>W</given-names></name><name><surname>Hothorn</surname><given-names>T</given-names></name><name><surname>Graeven</surname><given-names>U</given-names></name><name><surname>Arnold</surname><given-names>D</given-names></name><name><surname>Lang-Welzenbach</surname><given-names>M</given-names></name><name><surname>Raab</surname><given-names>HR</given-names></name><etal/></person-group><article-title>Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial trial</article-title><source>Lancet Oncol</source><volume>13</volume><fpage>679</fpage><lpage>687</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70187-0</pub-id><pub-id pub-id-type="pmid">22627104</pub-id></element-citation></ref>
<ref id="b3-or-42-01-0377"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><article-title>Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer</article-title><source>Mol Cancer Ther</source><volume>5</volume><fpage>1183</fpage><lpage>1189</lpage><year>2006</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-05-0400</pub-id><pub-id pub-id-type="pmid">16731750</pub-id></element-citation></ref>
<ref id="b4-or-42-01-0377"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Vanderwaal</surname><given-names>RP</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Gonzalez-Suarez</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Roti Roti</surname><given-names>JL</given-names></name><name><surname>Gonzalo</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>The mTOR inhibitor rapamycin suppresses DNA double-strand break repair</article-title><source>Radiat Res</source><volume>175</volume><fpage>214</fpage><lpage>224</lpage><year>2011</year><pub-id pub-id-type="doi">10.1667/RR2323.1</pub-id><pub-id pub-id-type="pmid">21268715</pub-id></element-citation></ref>
<ref id="b5-or-42-01-0377"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buijsen</surname><given-names>J</given-names></name><name><surname>van den Bogaard</surname><given-names>J</given-names></name><name><surname>Jutten</surname><given-names>B</given-names></name><name><surname>Belgers</surname><given-names>E</given-names></name><name><surname>Sosef</surname><given-names>M</given-names></name><name><surname>Leijtens</surname><given-names>JW</given-names></name><name><surname>Beets</surname><given-names>GL</given-names></name><name><surname>Jansen</surname><given-names>RL</given-names></name><name><surname>Riedl</surname><given-names>RG</given-names></name><name><surname>Clarijs</surname><given-names>R</given-names></name><etal/></person-group><article-title>A phase I&#x2013;II study on the combination of rapamycin and short course radiotherapy in rectal cancer</article-title><source>Radiother Oncol</source><volume>116</volume><fpage>214</fpage><lpage>220</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.radonc.2015.07.039</pub-id><pub-id pub-id-type="pmid">26253949</pub-id></element-citation></ref>
<ref id="b6-or-42-01-0377"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaurasia</surname><given-names>M</given-names></name><name><surname>Bhatt</surname><given-names>AN</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Dwarakanath</surname><given-names>BS</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name></person-group><article-title>Radiation-induced autophagy: Mechanisms and consequences</article-title><source>Free Radic Res</source><volume>50</volume><fpage>273</fpage><lpage>290</lpage><year>2016</year><pub-id pub-id-type="doi">10.3109/10715762.2015.1129534</pub-id><pub-id pub-id-type="pmid">26764568</pub-id></element-citation></ref>
<ref id="b7-or-42-01-0377"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Crosstalk between autophagy and intracellular radiation response (Review)</article-title><source>Int J Oncol</source><volume>49</volume><fpage>2217</fpage><lpage>2226</lpage><year>2016</year><pub-id pub-id-type="doi">10.3892/ijo.2016.3719</pub-id><pub-id pub-id-type="pmid">27748893</pub-id></element-citation></ref>
<ref id="b8-or-42-01-0377"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosich</surname><given-names>L</given-names></name><name><surname>Xargay-Torrent</surname><given-names>S</given-names></name><name><surname>L&#x00F3;pez-Guerra</surname><given-names>M</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Colomer</surname><given-names>D</given-names></name><name><surname>Rou&#x00E9;</surname><given-names>G</given-names></name></person-group><article-title>Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma</article-title><source>Clin Cancer Res</source><volume>18</volume><fpage>5278</fpage><lpage>5289</lpage><year>2012</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0351</pub-id><pub-id pub-id-type="pmid">22879389</pub-id></element-citation></ref>
<ref id="b9-or-42-01-0377"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>M</given-names></name><name><surname>Nozawa</surname><given-names>H</given-names></name><name><surname>Hiyoshi</surname><given-names>M</given-names></name><name><surname>Tada</surname><given-names>N</given-names></name><name><surname>Murono</surname><given-names>K</given-names></name><name><surname>Nirei</surname><given-names>T</given-names></name><name><surname>Emoto</surname><given-names>S</given-names></name><name><surname>Kishikawa</surname><given-names>J</given-names></name><name><surname>Iida</surname><given-names>Y</given-names></name><name><surname>Sunami</surname><given-names>E</given-names></name><etal/></person-group><article-title>Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells</article-title><source>J Cancer Res Clin Onco</source><volume>140</volume><fpage>769</fpage><lpage>781</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s00432-014-1628-0</pub-id></element-citation></ref>
<ref id="b10-or-42-01-0377"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>YK</given-names></name><name><surname>Xie</surname><given-names>WM</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>WX</given-names></name><name><surname>Wang</surname><given-names>HX</given-names></name><name><surname>Nong</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>YX</given-names></name><name><surname>Tan</surname><given-names>AH</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Inhibition of autophagy enhances the radiosensitivity of nasopharyngeal carcinoma by reducing Rad51 expression</article-title><source>Oncol Rep</source><volume>32</volume><fpage>1905</fpage><lpage>1912</lpage><year>2014</year><pub-id pub-id-type="doi">10.3892/or.2014.3427</pub-id><pub-id pub-id-type="pmid">25175062</pub-id></element-citation></ref>
<ref id="b11-or-42-01-0377"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>G</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1</article-title><source>Int J Cancer</source><volume>136</volume><fpage>1003</fpage><lpage>1012</lpage><year>2015</year><pub-id pub-id-type="doi">10.1002/ijc.29065</pub-id><pub-id pub-id-type="pmid">25044403</pub-id></element-citation></ref>
<ref id="b12-or-42-01-0377"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apel</surname><given-names>A</given-names></name><name><surname>Herr</surname><given-names>I</given-names></name><name><surname>Schwarz</surname><given-names>H</given-names></name><name><surname>Rodemann</surname><given-names>HP</given-names></name><name><surname>Mayer</surname><given-names>A</given-names></name></person-group><article-title>Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy</article-title><source>Cancer Res</source><volume>68</volume><fpage>1485</fpage><lpage>1494</lpage><year>2008</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0562</pub-id><pub-id pub-id-type="pmid">18316613</pub-id></element-citation></ref>
<ref id="b13-or-42-01-0377"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuno</surname><given-names>T</given-names></name><name><surname>Kawai</surname><given-names>K</given-names></name><name><surname>Hata</surname><given-names>K</given-names></name><name><surname>Murono</surname><given-names>K</given-names></name><name><surname>Emoto</surname><given-names>S</given-names></name><name><surname>Kaneko</surname><given-names>M</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Nozawa</surname><given-names>H</given-names></name></person-group><article-title>SN-38 Acts as a radiosensitizer for colorectal cancer by inhibiting the radiation-induced Up-regulation of HIF-1&#x03B1;</article-title><source>Anticancer Res</source><volume>38</volume><fpage>3323</fpage><lpage>3331</lpage><year>2018</year><pub-id pub-id-type="doi">10.21873/anticanres.12598</pub-id><pub-id pub-id-type="pmid">29848680</pub-id></element-citation></ref>
<ref id="b14-or-42-01-0377"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxton</surname><given-names>RA</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><article-title>mTOR signaling in growth, metabolism, and disease</article-title><source>Cell</source><volume>168</volume><fpage>960</fpage><lpage>976</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.cell.2017.02.004</pub-id><pub-id pub-id-type="pmid">28283069</pub-id><pub-id pub-id-type="pmcid">5394987</pub-id></element-citation></ref>
<ref id="b15-or-42-01-0377"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fingar</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>CJ</given-names></name><name><surname>Tee</surname><given-names>AR</given-names></name><name><surname>Cheatham</surname><given-names>L</given-names></name><name><surname>Tsou</surname><given-names>C</given-names></name><name><surname>Blenis</surname><given-names>J</given-names></name></person-group><article-title>mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E</article-title><source>Mol Cell Biol</source><volume>24</volume><fpage>200</fpage><lpage>216</lpage><year>2004</year><pub-id pub-id-type="doi">10.1128/MCB.24.1.200-216.2004</pub-id><pub-id pub-id-type="pmid">14673156</pub-id><pub-id pub-id-type="pmcid">303352</pub-id></element-citation></ref>
<ref id="b16-or-42-01-0377"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyasaka</surname><given-names>A</given-names></name><name><surname>Oda</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Sone</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>T</given-names></name><name><surname>Inaba</surname><given-names>K</given-names></name><name><surname>Makii</surname><given-names>C</given-names></name><name><surname>Enomoto</surname><given-names>A</given-names></name><name><surname>Hosoya</surname><given-names>N</given-names></name><name><surname>Tanikawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-&#x03B1;/VEGF pathway in endometrial cancer</article-title><source>Gynecol Oncol</source><volume>138</volume><fpage>174</fpage><lpage>180</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.ygyno.2015.04.015</pub-id><pub-id pub-id-type="pmid">25913131</pub-id></element-citation></ref>
<ref id="b17-or-42-01-0377"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>E</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Onishko</surname><given-names>H</given-names></name><name><surname>Donnelly</surname><given-names>E</given-names></name><name><surname>Hallahan</surname><given-names>DE</given-names></name></person-group><article-title>Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation</article-title><source>Cancer Res</source><volume>62</volume><fpage>4671</fpage><lpage>4677</lpage><year>2002</year><pub-id pub-id-type="pmid">12183424</pub-id></element-citation></ref>
<ref id="b18-or-42-01-0377"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikawa</surname><given-names>T</given-names></name><name><surname>Tsuno</surname><given-names>NH</given-names></name><name><surname>Okaji</surname><given-names>Y</given-names></name><name><surname>Shuno</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Hongo</surname><given-names>K</given-names></name><name><surname>Sunami</surname><given-names>E</given-names></name><name><surname>Kitayama</surname><given-names>J</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Nagawa</surname><given-names>H</given-names></name></person-group><article-title>Inhibition of autophagy potentiates sulforaphane-induced apoptosis in human colon cancer cells</article-title><source>Ann Surg Oncol</source><volume>17</volume><fpage>592</fpage><lpage>602</lpage><year>2010</year><pub-id pub-id-type="doi">10.1245/s10434-009-0696-x</pub-id><pub-id pub-id-type="pmid">19830499</pub-id></element-citation></ref>
<ref id="b19-or-42-01-0377"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Tsuno</surname><given-names>NH</given-names></name><name><surname>Sunami</surname><given-names>E</given-names></name><name><surname>Tsurita</surname><given-names>G</given-names></name><name><surname>Kawai</surname><given-names>K</given-names></name><name><surname>Okaji</surname><given-names>Y</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name><name><surname>Shuno</surname><given-names>Y</given-names></name><name><surname>Hongo</surname><given-names>K</given-names></name><name><surname>Hiyoshi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells</article-title><source>BMC Cancer</source><volume>10</volume><fpage>370</fpage><year>2010</year><pub-id pub-id-type="doi">10.1186/1471-2407-10-370</pub-id><pub-id pub-id-type="pmid">20630104</pub-id><pub-id pub-id-type="pmcid">2914703</pub-id></element-citation></ref>
<ref id="b20-or-42-01-0377"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Bari</surname><given-names>MA</given-names></name></person-group><article-title>Chloroquine analogues in drug discovery: New directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases</article-title><source>J Antimicrob Chemother</source><volume>70</volume><fpage>1608</fpage><lpage>1621</lpage><year>2015</year><pub-id pub-id-type="pmid">25693996</pub-id></element-citation></ref>
<ref id="b21-or-42-01-0377"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Subhawong</surname><given-names>T</given-names></name><name><surname>Albert</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Sekhar</surname><given-names>KR</given-names></name><name><surname>Gi</surname><given-names>YJ</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><article-title>Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN nulll prostate cancer cells</article-title><source>Cancer Res</source><volume>66</volume><fpage>10040</fpage><lpage>10047</lpage><year>2006</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0802</pub-id><pub-id pub-id-type="pmid">17047067</pub-id></element-citation></ref>
<ref id="b22-or-42-01-0377"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manegold</surname><given-names>PC</given-names></name><name><surname>Paringer</surname><given-names>C</given-names></name><name><surname>Kulka</surname><given-names>U</given-names></name><name><surname>Krimmel</surname><given-names>K</given-names></name><name><surname>Eichhorn</surname><given-names>ME</given-names></name><name><surname>Wilkowski</surname><given-names>R</given-names></name><name><surname>Jauch</surname><given-names>KW</given-names></name><name><surname>Guba</surname><given-names>M</given-names></name><name><surname>Bruns</surname><given-names>CJ</given-names></name></person-group><article-title>Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer</article-title><source>Clin Cancer Res</source><volume>14</volume><fpage>892</fpage><lpage>900</lpage><year>2008</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0955</pub-id><pub-id pub-id-type="pmid">18245553</pub-id></element-citation></ref>
<ref id="b23-or-42-01-0377"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomonaco</surname><given-names>SL</given-names></name><name><surname>Finniss</surname><given-names>S</given-names></name><name><surname>Xiang</surname><given-names>C</given-names></name><name><surname>Decarvalho</surname><given-names>A</given-names></name><name><surname>Umansky</surname><given-names>F</given-names></name><name><surname>Kalkanis</surname><given-names>SN</given-names></name><name><surname>Mikkelsen</surname><given-names>T</given-names></name><name><surname>Brodie</surname><given-names>C</given-names></name></person-group><article-title>The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells</article-title><source>Int J Cancer</source><volume>125</volume><fpage>717</fpage><lpage>722</lpage><year>2009</year><pub-id pub-id-type="doi">10.1002/ijc.24402</pub-id><pub-id pub-id-type="pmid">19431142</pub-id></element-citation></ref>
<ref id="b24-or-42-01-0377"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Urata</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>CY</given-names></name><name><surname>Doi</surname><given-names>H</given-names></name><name><surname>Kitazato</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>TS</given-names></name></person-group><article-title>Enhanced autophagy in colorectal cancer stem cells does not contribute to radio-resistance</article-title><source>Oncotarget</source><volume>7</volume><fpage>45112</fpage><lpage>45121</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.8972</pub-id><pub-id pub-id-type="pmid">27129175</pub-id><pub-id pub-id-type="pmcid">5216709</pub-id></element-citation></ref>
<ref id="b25-or-42-01-0377"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bristol</surname><given-names>ML</given-names></name><name><surname>Emery</surname><given-names>SM</given-names></name><name><surname>Maycotte</surname><given-names>P</given-names></name><name><surname>Thorburn</surname><given-names>A</given-names></name><name><surname>Chakradeo</surname><given-names>S</given-names></name><name><surname>Gewirtz</surname><given-names>DA</given-names></name></person-group><article-title>Autophagy inhibition for chemosensitization and radiosensitization in cancer: Do the preclinical data support this therapeutic strategy?</article-title><source>J Pharmacol Exp Ther</source><volume>344</volume><fpage>544</fpage><lpage>552</lpage><year>2013</year><pub-id pub-id-type="doi">10.1124/jpet.112.199802</pub-id><pub-id pub-id-type="pmid">23291713</pub-id><pub-id pub-id-type="pmcid">3583507</pub-id></element-citation></ref>
<ref id="b26-or-42-01-0377"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enzenmuller</surname><given-names>S</given-names></name><name><surname>Gonzalez</surname><given-names>P</given-names></name><name><surname>Debatin</surname><given-names>KM</given-names></name><name><surname>Fulda</surname><given-names>S</given-names></name></person-group><article-title>Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis</article-title><source>Anticancer Drugs</source><volume>24</volume><fpage>14</fpage><lpage>19</lpage><year>2013</year><pub-id pub-id-type="doi">10.1097/CAD.0b013e32835a36db</pub-id><pub-id pub-id-type="pmid">23111416</pub-id></element-citation></ref>
<ref id="b27-or-42-01-0377"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seitz</surname><given-names>C</given-names></name><name><surname>Hugle</surname><given-names>M</given-names></name><name><surname>Cristofanon</surname><given-names>S</given-names></name><name><surname>Tchoghandjian</surname><given-names>A</given-names></name><name><surname>Fulda</surname><given-names>S</given-names></name></person-group><article-title>The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk</article-title><source>Int J Cancer</source><volume>132</volume><fpage>2682</fpage><lpage>2693</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/ijc.27935</pub-id><pub-id pub-id-type="pmid">23151917</pub-id></element-citation></ref>
<ref id="b28-or-42-01-0377"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choo</surname><given-names>AY</given-names></name><name><surname>Yoon</surname><given-names>SO</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Roux</surname><given-names>PP</given-names></name><name><surname>Blenis</surname><given-names>J</given-names></name></person-group><article-title>Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation</article-title><source>Proc Natl Acad Sci USA</source><volume>105</volume><fpage>17414</fpage><lpage>17419</lpage><year>2008</year><pub-id pub-id-type="doi">10.1073/pnas.0809136105</pub-id><pub-id pub-id-type="pmid">18955708</pub-id></element-citation></ref>
<ref id="b29-or-42-01-0377"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>TT</given-names></name><name><surname>Yu</surname><given-names>XX</given-names></name><name><surname>Yan</surname><given-names>LJ</given-names></name><name><surname>Xiao</surname><given-names>HT</given-names></name></person-group><article-title>Research progress of hydroxychloroquine and autophagy inhibitors on cancer</article-title><source>Cancer Chemother Pharmacol</source><volume>79</volume><fpage>287</fpage><lpage>294</lpage><year>2017</year><pub-id pub-id-type="doi">10.1007/s00280-016-3197-1</pub-id><pub-id pub-id-type="pmid">27889812</pub-id></element-citation></ref>
<ref id="b30-or-42-01-0377"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boya</surname><given-names>P</given-names></name><name><surname>Gonzalez-Polo</surname><given-names>RA</given-names></name><name><surname>Poncet</surname><given-names>D</given-names></name><name><surname>Andreau</surname><given-names>K</given-names></name><name><surname>Vieira</surname><given-names>HL</given-names></name><name><surname>Roumier</surname><given-names>T</given-names></name><name><surname>Perfettini</surname><given-names>JL</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine</article-title><source>Oncogene</source><volume>22</volume><fpage>3927</fpage><lpage>3936</lpage><year>2003</year><pub-id pub-id-type="doi">10.1038/sj.onc.1206622</pub-id><pub-id pub-id-type="pmid">12813466</pub-id></element-citation></ref>
<ref id="b31-or-42-01-0377"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakhter</surname><given-names>AJ</given-names></name><name><surname>Sahu</surname><given-names>RP</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Kaufmann</surname><given-names>WK</given-names></name><name><surname>Androphy</surname><given-names>EJ</given-names></name><name><surname>Travers</surname><given-names>JB</given-names></name><name><surname>Naidu</surname><given-names>SR</given-names></name></person-group><article-title>Chloroquine promotes apoptosis in melanoma cells by inhibiting BH3 domain-mediated PUMA degradation</article-title><source>J Invest Dermatol</source><volume>133</volume><fpage>2247</fpage><lpage>2254</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/jid.2013.56</pub-id><pub-id pub-id-type="pmid">23370537</pub-id><pub-id pub-id-type="pmcid">3675185</pub-id></element-citation></ref>
<ref id="b32-or-42-01-0377"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rangwala</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>YC</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Algazy</surname><given-names>KM</given-names></name><name><surname>Evans</surname><given-names>TL</given-names></name><name><surname>Fecher</surname><given-names>LA</given-names></name><name><surname>Schuchter</surname><given-names>LM</given-names></name><name><surname>Torigian</surname><given-names>DA</given-names></name><name><surname>Panosian</surname><given-names>JT</given-names></name><name><surname>Troxel</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma</article-title><source>Autophagy</source><volume>10</volume><fpage>1391</fpage><lpage>1402</lpage><year>2014</year><pub-id pub-id-type="doi">10.4161/auto.29119</pub-id><pub-id pub-id-type="pmid">24991838</pub-id><pub-id pub-id-type="pmcid">4203516</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-or-42-01-0377" position="float">
<label>Figure 1.</label>
<caption><p>Ionizing radiation activates the mTOR pathway and induces autophagy in human colorectal cancer cells. HT-29 and SW480 cells were treated with ionizing radiation at a dose of 4 Gy and mTOR pathway activation and autophagy induction were investigated. (A) Western blot analysis of the mTOR pathway-related proteins, p-S6, total S6, p-4E-BP1, and total 4E-BP1; and autophagy-related proteins LC3B-II/I and SQSTM1/p62 in cell lines 24 h after radiotherapy. &#x03B2;-actin was used as the control. (B) Bar plots represent the relative expression levels of each protein, as determined via densitometric analysis. The mTOR pathway-related proteins were presented as the phosphorylated isoform ratios normalized by the respective total proteins. The autophagy-related proteins were presented as LC3-II/LC3-I ratios and the p62 expression levels were normalized to &#x03B2;-actin levels. The data are expressed as the mean &#x00B1; SD from the results of three independent experiments (n=3). &#x002A;P&#x003C;0.05. Unpaired Student&#x0027;s t-tests were used. (C) p-S6, total S6, and LC3B-II/I levels at different intervals after radiotherapy. (D) Line graphs represent the changes in the expression levels of p-S6/total S6 and LC3-II/LC3-I ratio, as determined via densitometric analysis. The data are expressed as the mean &#x00B1; SD (n=3). (E) Acridine orange staining and fluorescence microscopy results for the accumulation of acidic vesicular organelles (bright red fluorescence) in cell lines 24 h after radiotherapy. Scale bar, 20 &#x00B5;m. (F) Bar plots represent flow cytometric results for formation of acidic vesicular organelles in cell lines 24 h after radiotherapy. The values of each therapy group were standardized by the value of the control, without any treatment. The data are expressed as the mean &#x00B1; SD (n=3). &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01. One-way ANOVA was used. p-S6, phospho-S6 ribosomal protein; p-4E-BP1, phospho-eukaryotic translation initiation factor 4E-binding protein 1; SQSTM1, sequestosome-1.</p></caption>
<graphic xlink:href="OR-42-01-0377-g00.tif"/>
</fig>
<fig id="f2-or-42-01-0377" position="float">
<label>Figure 2.</label>
<caption><p>Combination of TEM and CQ increases the anti-proliferative effect of IR in HT-29 and SW480 cells. Cells were treated with 80 nM TEM and/or 20 &#x00B5;M CQ followed by several doses of IR. (A) Clonogenic assay results revealing the colony-forming ability of HT-29 and SW480 cells in the presence of different doses of IR with or without TEM and/or CQ. Based on the results of a two-way ANOVA, only the drug groups that significantly influenced the effect of IR at the individual radiation doses have been indicated. The data are expressed as the mean &#x00B1; SD (n=3); &#x002A;&#x002A;P&#x003C;0.01. Cells treated with combination of TEM and CQ vs. untreated cells at the individual IR doses. (B) Results of crystal violet staining revealing surviving cell colonies on 10 cm dishes. (C) Results of the MTS assay revealing proliferation of cells 3 days after 4 Gy radiotherapy with or without TEM and/or CQ. The values in each group were standardized by the value of the control without radiotherapy. The data are expressed as the mean &#x00B1; SD (n=3). &#x002A;P&#x003C;0.05. One-way ANOVA was used. TEM, temsirolimus; CQ, chloroquine; IR, ionizing radiation.</p></caption>
<graphic xlink:href="OR-42-01-0377-g01.tif"/>
</fig>
<fig id="f3-or-42-01-0377" position="float">
<label>Figure 3.</label>
<caption><p>Combination of TEM, CQ and IR downregulates mTOR pathway-related proteins and autophagy-related proteins in SW480 and HT-29 cells. The cells were treated with 80 nM TEM and/or 20 &#x00B5;M CQ followed by 4 Gy radiotherapy and examined 24 h after radiotherapy. (A) Western blot analysis of mTOR pathway- and autophagy-related proteins. (B) Bar plots represent the relative expression levels of mTOR-related proteins, p-S6/total S6, and p-4E-BP1/total 4E-BP1, as determined via densitometric analysis. The data are expressed as the mean &#x00B1; SD (n=3). &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01. One-way ANOVA was used. (C) Bar plots represent the relative expression levels of autophagy-related proteins, LC3-II/LC3-I ratios, and p62 levels. The data are expressed as the mean &#x00B1; SD (n=3). &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01. One-way ANOVA was used. (D) Bar plots represent flow cytometric results revealing the formation of acridine orange-stained acidic vesicular organelles in cells 24 h after radiotherapy. The values of each group were standardized by the value of the control without any treatment. The data are expressed as the mean &#x00B1; SD (n=3). &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01. One-way ANOVA was used. (E) Fluorescence microscopy images showing acridine orange-stained autophagic vesicles in cells. Scale bar, 20 &#x00B5;m. NS, not significant; TEM, temsirolimus; CQ, chloroquine; IR, ionizing radiation; p-S6, phospho-S6 ribosomal protein; p-4E-BP1, phospho-eukaryotic translation initiation factor 4E-binding protein 1.</p></caption>
<graphic xlink:href="OR-42-01-0377-g02.tif"/>
</fig>
<fig id="f4-or-42-01-0377" position="float">
<label>Figure 4.</label>
<caption><p>Combination of TEM, CQ and IR induces apoptosis in SW480 and HT-29 cells. The cells were treated with 80 nM TEM and/or 20 &#x00B5;M CQ followed by 4 Gy radiotherapy and examined 48 h after radiotherapy. (A) FACS analysis of apoptosis based on Annexin V and propidium iodide (PI) staining in different treatment groups. The cells in the upper-right and lower-right quadrants represent apoptotic cells. The data are expressed as the mean &#x00B1; SD (n=3). One-way ANOVA was used. (B) Bar graph revealing the summed relative number of apoptotic cells in the different treatment groups. The data are expressed as the mean &#x00B1; SD (n=3). &#x002A;&#x002A;P&#x003C;0.01. One-way ANOVA was used. (C) Percentage of cells with activated caspase-3/7, as detected using FACS analysis. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01. (D) Trypan blue staining revealed the percentage of dead cells in different treatment groups. The data are expressed as the mean &#x00B1; SD (n=3). &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01. One-way ANOVA was used. NS, not significant; TEM, temsirolimus; CQ, chloroquine; IR, ionizing radiation.</p></caption>
<graphic xlink:href="OR-42-01-0377-g03.tif"/>
</fig>
</floats-group>
</article>